CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free KNE Stock Alerts C$0.14 +0.01 (+3.70%) (As of 04/22/2024 05:22 PM ET) Add Compare Share Share Today's RangeC$0.14▼C$0.1450-Day RangeC$0.08▼C$0.1652-Week RangeC$0.05▼C$0.17Volume5,000 shsAverage Volume154,406 shsMarket CapitalizationC$18.46 millionP/E RatioN/ADividend Yield3.08%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesStock AnalysisChartEarningsHeadlines Get Kane Biotech alerts: Email Address Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About Kane Biotech Stock (CVE:KNE)Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.Read More KNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNE Stock News HeadlinesApril 23, 2024 | insidertrades.comKane Biotech Inc. (CVE:KNE) Director Sells C$260,000.00 in StockApril 17, 2024 | americanbankingnews.comKane Biotech (CVE:KNE) Trading Up 8%April 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 16, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary ProductsApril 16, 2024 | tmcnet.comKane Biotech to Host Investor WebinarApril 15, 2024 | msn.comDual Listed Biotech Firm Achieves Sale of Animal Health Interest, Sending Shares HigherApril 15, 2024 | stockhouse.comKane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary ProductsApril 14, 2024 | americanbankingnews.comKane Biotech (CVE:KNE) Shares Down 7.1% April 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 12, 2024 | barrons.com'Light Injuries': Harry Kane's Children In Munich Car AccidentApril 11, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal HealthApril 11, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - KNEApril 11, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - KNEMarch 29, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 27, 2024 | finance.yahoo.comKane Biotech Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comKane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal HealthMarch 8, 2024 | tmcnet.comKane Biotech Receives Bioscience Association Manitoba Company of the Year AwardFebruary 24, 2024 | msn.comChicago Blackhawks brace for Patrick Kane’s return — as a Detroit Red Wing: ‘It’s definitely weird’January 31, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Files New Patent on revyve Antimicrobial Wound Gel SprayJanuary 31, 2024 | financialpost.comKane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel SprayJanuary 31, 2024 | stockhouse.comKane Biotech Files New Patent on revyve(TM) Antimicrobial Wound Gel SprayJanuary 25, 2024 | markets.businessinsider.comKane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care SymposiumJanuary 18, 2024 | finance.yahoo.comKane Biotech Announces Special Meeting of ShareholdersDecember 29, 2023 | finance.yahoo.comKane Biotech Announces Correction to Press ReleaseNovember 29, 2023 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Improved Third Quarter 2023 Financial ResultsNovember 28, 2023 | finance.yahoo.comKane Biotech Announces Improved Third Quarter 2023 Financial ResultsNovember 2, 2023 | finanznachrichten.deKane Biotech Inc.: Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve Antimicrobial Wound Gel at Advanced Wound Care Fall ForumSee More Headlines Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/22/2024Next Earnings (Estimated)5/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:KNE CUSIPN/A CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,320,000.00 Net Margins-157.48% Pretax MarginN/A Return on EquityN/A Return on Assets-32.70% Debt Debt-to-Equity Ratio1,164.24 Current Ratio0.37 Quick Ratio0.39 Sales & Book Value Annual SalesC$2.74 million Price / Sales6.74 Cash FlowC$0.02 per share Price / Cash Flow8.50 Book ValueC($0.07) per share Price / Book-2.00Miscellaneous Outstanding Shares131,840,000Free FloatN/AMarket CapC$18.46 million OptionableNot Optionable Beta0.56 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Marc EdwardsPresident, CEO & DirectorMr. Ray DupuisChief Financial OfficerMr. Kevin ColePresident & CEO of STEM Animal Health IncMr. Dena MehrabanGeneral Manager of STEM Animal Health IncDr. Robert B. Huizinga CNeph(C) (Age 58)M.Sc., MSc(Epi), Ph.D., R.N., RN NNC, Executive Chairman & Member of Scientific Advisory Board Dr. Gregory S. Schultz Ph.D. (Age 74)Chief Scientific Officer & Member of Scientific Advisory Board Lorne GorberInvestor RelationsMs. Lori ChristofalosVice President of Quality & ComplianceMs. Wendy NachtigallDirector of MarketingNicole SendeyInvestor Relations AdviserMore ExecutivesKey CompetitorsCeaproCVE:CZOReunion NeuroscienceTSE:REUNNeptune Wellness SolutionsTSE:NEPTAntibe TherapeuticsTSE:ATELiberty BiopharmaCVE:LTYView All CompetitorsInsidersPhilip RenaudSold 2,000,000 sharesTotal: C$260,000.00 ($0.13/share)Richard J. RenaudBought 3,125,000 shares on 9/11/2023Total: C$250,000.00 ($0.08/share) KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed in 2024? Kane Biotech's stock was trading at C$0.08 at the start of the year. Since then, KNE stock has increased by 75.0% and is now trading at C$0.14. View the best growth stocks for 2024 here. When is Kane Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our KNE earnings forecast. How were Kane Biotech's earnings last quarter? Kane Biotech Inc. (CVE:KNE) announced its earnings results on Tuesday, March, 26th. The company reported ($0.01) EPS for the quarter. The company earned $0.04 million during the quarter. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:KNE) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
